Navigation Links
BIO Ventures for Global Health Announces Management Changes
Date:6/25/2009

Christopher D. Earl Resigning as CEO

Board member Melinda Moree named interim leader

WASHINGTON, June 25 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced that Christopher D. Earl, Ph.D., will resign from BVGH, effective July 9, 2009. Melinda Moree, Ph.D., a member of the board since BVGH's inception, will serve as interim CEO until a permanent replacement is hired.

"I've been galvanized by my experience in global health and honored to have the opportunity to contribute," says Dr. Earl. "I look forward to continuing to work at the interface of public health, science, and entrepreneurship."

"Chris's imagination and expertise have enabled BVGH to demonstrate the integral role the biotechnology industry can play in addressing the urgent medical needs of developing countries," says Robert B. Chess, Chairman of BVGH. "From promoting new financial incentives that reward companies for investing in global health R&D, to creating Innovation Maps that define a path toward making new breakthrough therapies, we thank Chris for his commitment and contributions. In particular, we are pleased that BVGH secured a three-year, $7 million renewal of funding from the Bill & Melinda Gates Foundation under Chris' leadership."

Melinda Moree, Ph.D., previously served as Executive Director for the PATH Malaria Vaccine Initiative, a $50 million/year Product Development Partnership funded by the Bill & Melinda Gates Foundation. She also served as Vice President, Global Health Services, Applied Strategies, supporting global, regional, and national health organizations in their mission to improve human health worldwide.

"BVGH has had an impact through initiatives launched by Chris such as last year's Partnering for Global Health Forum that brought together biotechnology executives and global health innovators," says Jim Greenwood, President and CEO of the Biotechnology Industry Organization and a member of the BVGH Board. "We look forward to continued success through Melinda's knowledge of BVGH and depth of experience in forging partnerships between the private and public sectors to keep BVGH operating at a high level."

About BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for infectious diseases of the developing world. BVGH breaks down barriers that hinder industry initiatives in global health product development. We foster collaboration among stakeholders in industry, philanthropy, academia, and government, and we catalyze industry investment through the creation of new market-based incentives. For more information please visit www.bvgh.org.


'/>"/>
SOURCE BIO Ventures for Global Health
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... Discovering new clues to natural treatments that could allow ... in our brains. And searching for keys to our immune systems by studying parasite-resistant ... the 2017 Edith and Peter O’Donnell Awards by The Academy of ...
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical ... it has acquired the assets of Theorem Clinical Research - Clinical Supplies ... clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials ...
(Date:12/6/2016)... 2016 Zimmer Biomet Holdings, Inc. (NYSE ... pricing terms of its previously-announced cash tender offers ... price (excluding accrued and unpaid interest to, but ... fees and expenses related to the Offers) (the ... in the table below (collectively, the "Notes"). The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) inhibited the direct neurotoxic effect of prion-like forms of Amyloid ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/22/2016)... -- According to the new market research report "Biometric System ... Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and ... expected to grow from USD 10.74 Billion in 2015 to reach USD ... 2022. Continue Reading ... ...
(Date:11/17/2016)...  AIC announces that it has just released a new white paper authored by ... plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can ...
Breaking Biology News(10 mins):